From Code to Cure: AI’s Role in the Drug Development and Clinical Trials

From Code to Cure: AI’s Role in Drug Development and Clinical Trials

Join us for an exclusive evening exploring how artificial intelligence is transforming the pharmaceutical landscape, from early-stage drug discovery to real-world clinical trials.

This event, hosted by Recipharm, brings together leading voices from biotech, healthcare, and academia to discuss the real-world impact of AI in pharma.

Our speakers includes:

Yogev Debbi (ManaBio, CEO): "AI-Driven design of Lipid Nanoparticles for RNA Delivery"

Prof. Boaz Lerner (Ben-Gurion University / Panacea, founder): "Developing AI models to optimize clinical trial design"

Marina Naomi Smolyanov (Clalit Health Services, Innovation Operation Manager): "AI in Action: Driving Scalable Innovation in Public Healthcare Systems"

Whether you're in biotech, pharma, healthcare, or data science, this is your chance to gain insights, ask questions, and network with professionals shaping the future of medicine.

Yogev Debbi

Title: CEO & Co-Founder, ManaBio
Yogev Debbi is the Co-founder and CEO of Mana.bio, an AI-driven drug delivery company leveraging machine learning and high-throughput screening to develop tissue-specific lipid nanoparticle (LNP) delivery solutions. Under his leadership, Mana.bio has pioneered a data-driven approach to unlocking extrahepatic delivery of nucleic acid therapeutics.
Prior to founding Mana.bio, Yogev co-founded Genome Compiler, a leading gene editing software platform that was acquired by Twist Bioscience (Nasdaq: TWST), a global leader in synthetic biology. Following the acquisition, he served as General Manager of Twist’s Israel R&D center, playing a key role in the company's IPO.
Yogev later held a senior leadership position at monday.com (Nasdaq: MNDY), contributing to its successful IPO and growth as a global enterprise software leader.

In his talk, "AI-Driven design of Lipid Nanoparticles for RNA Delivery" Yogev will discuss how Mana.bio integrates machine learning with high-throughput screening to develop tissue-specific LNPs that enable targeted delivery of RNA therapeutics beyond the liver (extrahepatic delivery). He will highlight the company’s innovative, data-driven approach to overcoming one of the most significant challenges in nucleic acid drug delivery.

Prof. Boaz Lerner

Title: Professor, Ben-Gurion University | Founder, Panacea
Boaz Lerner is a professor of Machine Learning and Data Science at Ben-Gurion University, known for his pioneering work in machine learning, graphical models, and applications in biomedicine. He is also the founder of Panacea-ml, a company leveraging explainable AI to revolutionizes clinical trial design with its data-driven SaaS platform. In his research he develops predictive and explainable machine-learning models and decision support systems in digital healthcare.
In his talk about "Developing AI models to optimize clinical trial design"
Boaz will focus on how AI is reshaping the drug development pipeline at the clinical trials.

Marina Naomi Smolyanov

Title: Innovation Leader, Clalit Health Services
Marina Naomi Smolyanov is a leading figure in healthcare innovation at Clalit, the largest and most advanced health organization in Israel. With a background in digital health strategy and cross-sector collaboration, she focuses on integrating AI and emerging technologies into clinical workflows. Her work bridges the gap between healthcare providers, startups, and research institutions to drive scalable, patient-centered innovation.

In her talk about "AI in Action: Driving Scalable Innovation in Public Healthcare Systems"
Marina will focus on how AI is being implemented in large-scale healthcare environments, lessons learned from Clalit’s innovation journey, and the future of digital transformation in public health.